ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 196,44
0,65%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ABVC BioPharma Inc (ABVC)

  7. ABVC BioPharma Inc (ABVC) Actualités

ABVC

ABVC BioPharma (ABVC)

ABVC BioPharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ABVC
DateHeureSourceTitreSymboleSociété
09/05/202415h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
18/04/202415h25GlobeNewswire Inc.AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareNASDAQ:ABVCABVC BioPharma Inc
17/04/202415h00GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MNASDAQ:ABVCABVC BioPharma Inc
10/04/202414h30GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MNASDAQ:ABVCABVC BioPharma Inc
26/03/202413h30GlobeNewswire Inc.ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MNASDAQ:ABVCABVC BioPharma Inc
21/03/202413h30GlobeNewswire Inc.AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsNASDAQ:ABVCABVC BioPharma Inc
19/03/202413h30GlobeNewswire Inc.ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineNASDAQ:ABVCABVC BioPharma Inc
14/03/202414h30GlobeNewswire Inc.ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateNASDAQ:ABVCABVC BioPharma Inc
29/02/202422h32Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
27/02/202414h30GlobeNewswire Inc.ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsNASDAQ:ABVCABVC BioPharma Inc
16/02/202423h04Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ABVCABVC BioPharma Inc
15/02/202414h30GlobeNewswire Inc.ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesNASDAQ:ABVCABVC BioPharma Inc
14/02/202401h59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABVCABVC BioPharma Inc
12/02/202414h30GlobeNewswire Inc.ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)NASDAQ:ABVCABVC BioPharma Inc
08/02/202415h17GlobeNewswire Inc.ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per ShareNASDAQ:ABVCABVC BioPharma Inc
12/01/202423h01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ABVCABVC BioPharma Inc
03/01/202413h24GlobeNewswire Inc.ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing FeesNASDAQ:ABVCABVC BioPharma Inc
07/12/202314h30GlobeNewswire Inc.ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
05/12/202314h30GlobeNewswire Inc.ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsNASDAQ:ABVCABVC BioPharma Inc
21/11/202314h30GlobeNewswire Inc.ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNASDAQ:ABVCABVC BioPharma Inc
17/11/202323h00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
17/11/202323h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ABVCABVC BioPharma Inc
16/11/202316h05GlobeNewswire Inc.ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MNASDAQ:ABVCABVC BioPharma Inc
15/11/202315h00GlobeNewswire Inc.ABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsNASDAQ:ABVCABVC BioPharma Inc
15/11/202314h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABVCABVC BioPharma Inc
26/10/202314h30GlobeNewswire Inc.ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 MillionNASDAQ:ABVCABVC BioPharma Inc
17/10/202314h30GlobeNewswire Inc.ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
09/10/202314h30GlobeNewswire Inc.ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)NASDAQ:ABVCABVC BioPharma Inc
23/08/202314h30GlobeNewswire Inc.ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
17/08/202315h19GlobeNewswire Inc.ABVC Executes Cooperation Agreement for Strategic InvestmentsNASDAQ:ABVCABVC BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:ABVC

Dernières Valeurs Consultées

KOSPI
510015
Daishin Wheat Futures Et...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés